Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2008, p. 45-53, Vol. 52, No. 1
0066-4804/08/$08.00+0 doi:10.1128/AAC.00534-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Mutated Response Regulator graR Is Responsible for Phenotypic Conversion of Staphylococcus aureus from Heterogeneous Vancomycin-Intermediate Resistance to Vancomycin-Intermediate Resistance
Hui-min Neoh,1
Longzhu Cui,1,2
Harumi Yuzawa,1
Fumihiko Takeuchi,2
Miki Matsuo,1 and
Keiichi Hiramatsu1,2*
Department of Bacteriology,1
Department of Infection Control Science, Faculty of Medicine, Juntendo University, 2-1-1 Bunkyo-Ku, Tokyo, Japan 113-84212
Received 23 April 2007/
Returned for modification 7 May 2007/
Accepted 9 October 2007
Multistep genetic alteration is required for methicillin-resistant Staphylococcus aureus (MRSA) to achieve the level of vancomycin resistance of vancomycin-intermediate S. aureus (VISA). In the progression of vancomycin resistance, strains with heterogeneous vancomycin resistance, designated hetero-VISA, are observed. In studying the whole-genome sequencing of the representative hetero-VISA strain Mu3 and comparing it with that of closely related MRSA strains Mu50 (VISA) and N315 (vancomycin-susceptible S. aureus [VSSA]), we identified a mutation in the response regulator of the graSR two-component regulatory system. Introduction of mutated graR, designated graR*, but not intact graR, designated graRn, could convert the hetero-VISA phenotype of Mu3 into a VISA phenotype which was comparable to that of Mu50. The same procedure did not appreciably increase the vancomycin resistance of VSSA strain N315, indicating that graR* expression was effective only in the physiological milieu of hetero-VISA cell to achieve a VISA phenotype. Interestingly, the overexpression of graR* increased the daptomycin MICs in both Mu3 and N315 and decreased the oxacillin MIC in N315.
* Corresponding author. Mailing address: Department of Bacteriology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan 113-8421. Phone: (813) 3-5802-1040. Fax: (813) 3-5684-7830. E-mail:
khiram06{at}med.juntendo.ac.jp
Published ahead of print on 22 October 2007.
Antimicrobial Agents and Chemotherapy, January 2008, p. 45-53, Vol. 52, No. 1
0066-4804/08/$08.00+0 doi:10.1128/AAC.00534-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Holden, M. T. G., Lindsay, J. A., Corton, C., Quail, M. A., Cockfield, J. D., Pathak, S., Batra, R., Parkhill, J., Bentley, S. D., Edgeworth, J. D.
(2010). Genome Sequence of a Recently Emerged, Highly Transmissible, Multi-Antibiotic- and Antiseptic-Resistant Variant of Methicillin-Resistant Staphylococcus aureus, Sequence Type 239 (TW). J. Bacteriol.
192: 888-892
[Abstract]
[Full Text]
-
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., Grayson, M. L.
(2010). Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications. Clin. Microbiol. Rev.
23: 99-139
[Abstract]
[Full Text]
-
Kato, Y., Suzuki, T., Ida, T., Maebashi, K.
(2010). Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. J Antimicrob Chemother
65: 37-45
[Abstract]
[Full Text]
-
Katayama, Y., Murakami-Kuroda, H., Cui, L., Hiramatsu, K.
(2009). Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem. Antimicrob. Agents Chemother.
53: 3190-3196
[Abstract]
[Full Text]
-
Ng, J. W. S., Holt, D. C., Lilliebridge, R. A., Stephens, A. J., Huygens, F., Tong, S. Y. C., Currie, B. J., Giffard, P. M.
(2009). Phylogenetically Distinct Staphylococcus aureus Lineage Prevalent among Indigenous Communities in Northern Australia. J. Clin. Microbiol.
47: 2295-2300
[Abstract]
[Full Text]
-
Renzoni, A., Kelley, W. L., Barras, C., Monod, A., Huggler, E., Francois, P., Schrenzel, J., Studer, R., Vaudaux, P., Lew, D. P.
(2009). Identification by Genomic and Genetic Analysis of Two New Genes Playing a Key Role in Intermediate Glycopeptide Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.
53: 903-911
[Abstract]
[Full Text]
-
Cui, L., Neoh, H.-m., Shoji, M., Hiramatsu, K.
(2009). Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother.
53: 1231-1234
[Abstract]
[Full Text]
-
Kirby, A., Mohandas, K., Broughton, C., Neal, T. J., Smith, G. W., Pai, P., Nistal de Paz, C.
(2009). In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. J Med Microbiol
58: 376-380
[Abstract]
[Full Text]
-
Baba, T., Kuwahara-Arai, K., Uchiyama, I., Takeuchi, F., Ito, T., Hiramatsu, K.
(2009). Complete Genome Sequence of Macrococcus caseolyticus Strain JSCS5402, Reflecting the Ancestral Genome of the Human-Pathogenic Staphylococci. J. Bacteriol.
191: 1180-1190
[Abstract]
[Full Text]
-
Camargo, I. L. B. d. C., Neoh, H.-M., Cui, L., Hiramatsu, K.
(2008). Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype. Antimicrob. Agents Chemother.
52: 4289-4299
[Abstract]
[Full Text]
-
Warren, R. E.
(2008). Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother
62: iii25-iii33
[Abstract]
[Full Text]
-
Howden, B. P., Stinear, T. P., Allen, D. L., Johnson, P. D. R., Ward, P. B., Davies, J. K.
(2008). Genomic Analysis Reveals a Point Mutation in the Two-Component Sensor Gene graS That Leads to Intermediate Vancomycin Resistance in Clinical Staphylococcus aureus. Antimicrob. Agents Chemother.
52: 3755-3762
[Abstract]
[Full Text]